TABLE 3.
Isavuconazole PPK parameters in the VITAL study, based on underlying diseasea
| Underlying disease (n)b | CL (liters/h) (mean ± SD) | V (liters) (mean ± SD) | AUCavg (mg · h/liter) (mean ± SD) | %CV of CL | F (%) |
|---|---|---|---|---|---|
| Overall (136) | 2.5 ± 1.6 | 361.2 ± 166.3 | 87.1 ± 41.0 | 63 | 96.6 |
| Hematologic malignancy (56) | 2.6 ± 1.6 | 378.7 ± 171.0 | 85.1 ± 50.2 | 60 | 96.2 |
| Active (at baseline) malignancy (41) | 2.6 ± 1.6 | 382.2 ± 165.3 | 84.4 ± 54.0 | 59 | 95.9 |
| Baseline neutropenia (34) | 2.7 ± 1.8 | 406.3 ± 168.0 | 82.8 ± 57.9 | 59 | 96.0 |
| Combined hematologic malignancy, active (at baseline) malignancy, and baseline neutropenia (24) | 2.8 ± 1.8 | 391.7 ± 187.2 | 85.1 ± 68.0 | 62 | 94.7 |
| Nonec (71) | 2.8 ± 1.8 | 391.8 ± 187.2 | 85.1 ± 68.0 | 62 | 94.7 |
a
CL, clearance; V, volume in the central compartment; %CV, percent covariance of intersubject variability; F, bioavailability.
b
Patients in each category are not mutually exclusive.
c
Patients without hematologic malignancy, active (at baseline) malignancy, or baseline neutropenia.